Selected research
Industry Research
NGAL Antibody Industry Research Report 2026
Market perspective
The global NGAL Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the NGAL Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the NGAL Antibody market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the NGAL Antibody market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of NGAL Antibody include Thermo Fisher Scientific, Abcam, Hytest, Enzo Life Sciences, Biorbyt, Proteintech, Biomatik, Bio-Techne and MyBioSource, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global NGAL Antibody market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to NGAL Antibody.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
NGAL Antibody Market by Company
Thermo Fisher Scientific
Abcam
Hytest
Enzo Life Sciences
Biorbyt
Proteintech
Biomatik
Bio-Techne
MyBioSource
GenScript
Bioss
BioNC
NGAL Antibody Segment by Type
Monoclonal Antibody
Polyclonal Antibody
NGAL Antibody Segment by Application
Clinic
Scientific Research
NGAL Antibody Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGAL Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NGAL Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGAL Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of NGAL Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibody
- Polyclonal Antibody
Applications
- Clinic
- Scientific Research
Companies covered
- Thermo Fisher Scientific
- Abcam
- Hytest
- Enzo Life Sciences
- Biorbyt
- Proteintech
- Biomatik
- Bio-Techne
- MyBioSource
- GenScript
- Bioss
- BioNC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 NGAL Antibody by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Monoclonal Antibody
- 2.2.3 Polyclonal Antibody
- 2.3 NGAL Antibody by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinic
- 2.3.3 Scientific Research
- 2.4 Assumptions and Limitations
3 NGAL Antibody Breakdown Data by Type
- 3.1 Global NGAL Antibody Historic Market Size by Type (2021-2026)
- 3.2 Global NGAL Antibody Forecasted Market Size by Type (2027-2032)
4 NGAL Antibody Breakdown Data by Application
- 4.1 Global NGAL Antibody Historic Market Size by Application (2021-2026)
- 4.2 Global NGAL Antibody Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global NGAL Antibody Market Perspective (2021-2032)
- 5.2 Global NGAL Antibody Growth Trends by Region
- 5.2.1 Global NGAL Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 NGAL Antibody Historic Market Size by Region (2021-2026)
- 5.2.3 NGAL Antibody Forecasted Market Size by Region (2027-2032)
- 5.3 NGAL Antibody Market Dynamics
- 5.3.1 NGAL Antibody Industry Trends
- 5.3.2 NGAL Antibody Market Drivers
- 5.3.3 NGAL Antibody Market Challenges
- 5.3.4 NGAL Antibody Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top NGAL Antibody Players by Revenue
- 6.1.1 Global Top NGAL Antibody Players by Revenue (2021-2026)
- 6.1.2 Global NGAL Antibody Revenue Market Share by Players (2021-2026)
- 6.2 Global NGAL Antibody Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of NGAL Antibody Head Office and Area Served
- 6.4 Global NGAL Antibody Players, Product Type & Application
- 6.5 Global NGAL Antibody Manufacturers Established Date
- 6.6 Global NGAL Antibody Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America NGAL Antibody Market Size (2021-2032)
- 7.2 North America NGAL Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America NGAL Antibody Market Size by Country (2021-2026)
- 7.4 North America NGAL Antibody Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe NGAL Antibody Market Size (2021-2032)
- 8.2 Europe NGAL Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe NGAL Antibody Market Size by Country (2021-2026)
- 8.4 Europe NGAL Antibody Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific NGAL Antibody Market Size (2021-2032)
- 9.2 Asia-Pacific NGAL Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific NGAL Antibody Market Size by Country (2021-2026)
- 9.4 Asia-Pacific NGAL Antibody Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America NGAL Antibody Market Size (2021-2032)
- 10.2 South America NGAL Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America NGAL Antibody Market Size by Country (2021-2026)
- 10.4 South America NGAL Antibody Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa NGAL Antibody Market Size (2021-2032)
- 11.2 Middle East & Africa NGAL Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa NGAL Antibody Market Size by Country (2021-2026)
- 11.4 Middle East & Africa NGAL Antibody Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Thermo Fisher Scientific
- 12.1.1 Thermo Fisher Scientific Company Information
- 12.1.2 Thermo Fisher Scientific Business Overview
- 12.1.3 Thermo Fisher Scientific Revenue in NGAL Antibody Business (2021-2026)
- 12.1.4 Thermo Fisher Scientific NGAL Antibody Product Portfolio
- 12.1.5 Thermo Fisher Scientific Recent Developments
- 12.2 Abcam
- 12.2.1 Abcam Company Information
- 12.2.2 Abcam Business Overview
- 12.2.3 Abcam Revenue in NGAL Antibody Business (2021-2026)
- 12.2.4 Abcam NGAL Antibody Product Portfolio
- 12.2.5 Abcam Recent Developments
- 12.3 Hytest
- 12.3.1 Hytest Company Information
- 12.3.2 Hytest Business Overview
- 12.3.3 Hytest Revenue in NGAL Antibody Business (2021-2026)
- 12.3.4 Hytest NGAL Antibody Product Portfolio
- 12.3.5 Hytest Recent Developments
- 12.4 Enzo Life Sciences
- 12.4.1 Enzo Life Sciences Company Information
- 12.4.2 Enzo Life Sciences Business Overview
- 12.4.3 Enzo Life Sciences Revenue in NGAL Antibody Business (2021-2026)
- 12.4.4 Enzo Life Sciences NGAL Antibody Product Portfolio
- 12.4.5 Enzo Life Sciences Recent Developments
- 12.5 Biorbyt
- 12.5.1 Biorbyt Company Information
- 12.5.2 Biorbyt Business Overview
- 12.5.3 Biorbyt Revenue in NGAL Antibody Business (2021-2026)
- 12.5.4 Biorbyt NGAL Antibody Product Portfolio
- 12.5.5 Biorbyt Recent Developments
- 12.6 Proteintech
- 12.6.1 Proteintech Company Information
- 12.6.2 Proteintech Business Overview
- 12.6.3 Proteintech Revenue in NGAL Antibody Business (2021-2026)
- 12.6.4 Proteintech NGAL Antibody Product Portfolio
- 12.6.5 Proteintech Recent Developments
- 12.7 Biomatik
- 12.7.1 Biomatik Company Information
- 12.7.2 Biomatik Business Overview
- 12.7.3 Biomatik Revenue in NGAL Antibody Business (2021-2026)
- 12.7.4 Biomatik NGAL Antibody Product Portfolio
- 12.7.5 Biomatik Recent Developments
- 12.8 Bio-Techne
- 12.8.1 Bio-Techne Company Information
- 12.8.2 Bio-Techne Business Overview
- 12.8.3 Bio-Techne Revenue in NGAL Antibody Business (2021-2026)
- 12.8.4 Bio-Techne NGAL Antibody Product Portfolio
- 12.8.5 Bio-Techne Recent Developments
- 12.9 MyBioSource
- 12.9.1 MyBioSource Company Information
- 12.9.2 MyBioSource Business Overview
- 12.9.3 MyBioSource Revenue in NGAL Antibody Business (2021-2026)
- 12.9.4 MyBioSource NGAL Antibody Product Portfolio
- 12.9.5 MyBioSource Recent Developments
- 12.10 GenScript
- 12.10.1 GenScript Company Information
- 12.10.2 GenScript Business Overview
- 12.10.3 GenScript Revenue in NGAL Antibody Business (2021-2026)
- 12.10.4 GenScript NGAL Antibody Product Portfolio
- 12.10.5 GenScript Recent Developments
- 12.11 Bioss
- 12.11.1 Bioss Company Information
- 12.11.2 Bioss Business Overview
- 12.11.3 Bioss Revenue in NGAL Antibody Business (2021-2026)
- 12.11.4 Bioss NGAL Antibody Product Portfolio
- 12.11.5 Bioss Recent Developments
- 12.12 BioNC
- 12.12.1 BioNC Company Information
- 12.12.2 BioNC Business Overview
- 12.12.3 BioNC Revenue in NGAL Antibody Business (2021-2026)
- 12.12.4 BioNC NGAL Antibody Product Portfolio
- 12.12.5 BioNC Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst